Pitchbook US template - PowerPoint PPT Presentation

1 / 25
About This Presentation
Title:

Pitchbook US template

Description:

The 3rd International Longevity Risk and Capital Market Solutions Symposium ... Reverse mortgage, healthcare) 3. A N E W M A R K E T I S E M E R G I N G ... – PowerPoint PPT presentation

Number of Views:42
Avg rating:3.0/5.0
Slides: 26
Provided by: ppsde118
Category:

less

Transcript and Presenter's Notes

Title: Pitchbook US template


1
2 0   J U L Y   2 0 0 7
The 3rd International Longevity Risk and Capital
Market Solutions Symposium
Westin Hotel, Taipei, Taiwan
SM
L O N G E V I T Y   R I S K   T R A N S F E R  
 C A P I T A L   M A R K E T   S O L U T I O N S 
S T R I C T L Y   P R I V A T E   A N D 
 C O N F I D E N T I A L
GUY COUGHLAN, Managing Director, Global Head of
Pension ALM Advisory, JPMorgan
2
L O N G E V I T Y   R I S K   T R A N S F E R  
 C A P I T A L   M A R K E T   S O L U T I O N S 
This material is not an offer or solicitation for
the purchase or sale of any financial instrument,
nor is it a commitment by J.P. Morgan Chase Co.
or any of its subsidiaries (collectively,
JPMorgan) to enter into any transaction
referenced herein. Any commentary/trade idea
included herein was prepared by sales or trading
personnel and does not represent the views of any
JPMorgan research analyst. All information
herein is indicative, is based on certain
assumptions and current market conditions and is
subject to change without notice. Accordingly,
no reliance should be placed on the information
herein. When making an investment decision, an
investor should rely solely on the final
documentation relating to any referenced
transaction, which will contain the definitive
terms and conditions of the transaction.
JPMorgan makes no representation or warranty
regarding the accuracy or completeness of the
information herein. JPMorgan is not an advisor
to any investor in respect of any referenced
transaction. Each investor must make an
independent assessment of any legal, credit, tax,
regulatory and accounting issues and determine
with its own professional advisors any
suitability or appropriateness implications of
any transaction referenced herein in the context
of its particular circumstances. JPMorgan
assumes no responsibility or liability whatsoever
to any person in respect of such matters.
JPMorgan, or any connected or associated person,
may hold a long or short position or a derivative
interest in, or act as a market maker in, the
financial instruments of any issuer referred to
herein or act as underwriter, distributor,
advisor or lender to any such issuer. This
material is specific to the recipient and must
not be distributed to any other person or
replicated in any form without the prior written
consent JPMorgan. This material is directed
exclusively at market professionals and
institutional investors and is not for
distribution in any jurisdiction to private
customers, as defined by the rules of the
Financial Services Authority (FSA). Private
customers may not therefore rely on this
material. Moreover, any investment or services
to which this material may relate will not be
made available to private customers. Investors
should execute transactions through an authorised
entity in their home jurisdiction unless
governing law otherwise permits. J.P. Morgan
Securities Ltd., J.P. Morgan plc., J.P. Morgan
Europe Limited and JPMorgan Chase Bank, London
Branch are each authorised by the FSA.
3
A new market is emerging
1
1
Issues in hedging longevity risk
2
9
Longevity risk transfer products in the capital
markets
3
15
L O N G E V I T Y   R I S K   T R A N S F E R  
 C A P I T A L   M A R K E T   S O L U T I O N S 
1
4
Longevity appears to be a good candidate to
become a new market
  • Because
  • Longevity risk is transferable in principal
  • Risk transfer is feasible
  • Longevity exposure is economically significant
  • gt20 trillion globally
  • Longevity exposure cannot be hedged in existing
    markets
  • Not highly correlated with other markets
  • But market development also requires
  • Standardisation to create liquidity
  • Standardised Index
  • Standardised risk-transfer instruments
  • Standardised vocabulary/language
  • Education of market participants
  • Longevity is an unfamiliar risk

A   N E W   M A R K E T   I S   E M E R G I N G
2
5
Potential longevity risk landscape
Buyers of longevity risk protection
Sellers of longevity risk protection
Pension Funds
  • Pension liabilities exposed to longevity risk
  • Current tables likely underestimate risk
  • Beginning to evaluate impact of this risk
  • Could write protection to synthetically gain
  • exposure to risk
  • Have the sophistication to analyse risk return

Annuity Providers
  • Exposed to longevity risk through annuity
  • policies
  • Would look to hedge exposure

Life Insurance Companies
  • Exposed to declines in longevity through life
  • insurance policies
  • Selling longevity risk protection offsets this
    risk

Life Settlement/ Premium Finance Investor
  • Exposed to longevity risk through investment
  • portfolio
  • Buy protection to hedge general trend risk
  • Sell protection and earn premium
  • Can use existing expertise to evaluate risk
  • return

Pension Buyout Funds
  • Can use existing expertise to evaluate risk
  • return
  • May synthetically add exposure
  • Buy protection against longevity risks from
  • plan acquisition

A   N E W   M A R K E T   I S   E M E R G I N G
ILS Investors
  • Provide protection and earn premium

Other Hedge Funds
  • Have liquidity and seeking return

Endowments
  • Have liquidity and ability to buy hold
  • Long term investors
  • Innovators
  • Could issue debt
  • Naturally exposed to declines in longevity

Pharma
Others (eg. Reverse mortgage, healthcare)
3
6
There is capital seeking to be deployed on both
sides of the market
Longevity risk sellers
Longevity risk buyers
  • Pension plans and annuity providers
  • Several are already looking to hedge at least
    some part of their longevity exposure
  • Investors see longevity as a new asset class
    enabling them to
  • Earn a risk premium
  • Gain exposure to an uncorrelated asset class

A   N E W   M A R K E T   I S   E M E R G I N G
Want customised hedges to maximise
effectiveness
Want standardised investments to maximise
liquidity
Risk transfer products need to balance these
opposing needs
4
7
There are still challenges in developing a traded
market of sufficient liquidity
  • Barriers to creating a market
  • Low visibility of longevity risk
  • Perceived complexity
  • Unfamiliar nature of longevity risk
  • Lack of common language among different
    participants
  • Lack of credible risk transfer instruments
  • Addressing these challenges requires
  • Indices that are objective and transparent
  • Education of market participants
  • Standardisation of language
  • Appropriate risk transfer products

A   N E W   M A R K E T   I S   E M E R G I N G
This was the motivation behind the development of
LifeMetrics
5
8
LifeMetrics has been developed to promote
effective management of longevity and mortality
risk
A   N E W   M A R K E T   I S   E M E R G I N G
6
9
Current and historic data available on website
and Bloomberg
  • www.lifemetrics.com
  • Increase visibility of
  • Current mortality and longevity
  • Risk to future mortality and longevity
  • Data on
  • Crude mortality rates
  • Graduated mortality rates
  • Period life expectancy
  • Broken down by
  • Gender
  • Age
  • Country
  • Period

A   N E W   M A R K E T   I S   E M E R G I N G
7
10
Framework for longevity/mortality risk management
is fully documented
  • Framework described in 100-page LifeMetrics
    Technical Document and 80-page Research
    Discussion Paper
  • Technical Document
  • Transparent description of the LifeMetrics Index
    and how it is calculated
  • Details the approach to measuring and managing
    longevity/mortality risk
  • Coughlan et al. (2007)
  • Research Paper
  • Evaluates and compares different models of
    mortality projection
  • Cairns et al. (2007)

A   N E W   M A R K E T   I S   E M E R G I N G
8
11
Issues in hedging longevity risk
A new market is emerging
1
1
2
9
Longevity risk transfer products in the capital
markets
3
15
L O N G E V I T Y   R I S K   T R A N S F E R  
 C A P I T A L   M A R K E T   S O L U T I O N S 
9
12
There two broad categories of longevity risk
Standardised Longevity Hedge
Customised Longevity Hedge
  • Standardised to reflect national population
    longevity experience
  • But calibrated to match mortality sensitivity of
    pension
  • Structured as a value hedge
  • Maturity of Hedge
  • E.g. 10 years or 20 years
  • Tailored to reflect actual longevity experience
    of the pension plan
  • Structured as a cash flow hedge
  • Maturity of Hedge
  • Until the last member dies

I S S U E S   I N   H E D G I N G 
 L O N G E V I T Y   R I S K
Hedge Provider
Hedge Provider
Pension Plan
Fixed longevity
Actual longevity
10
13
Advantages and disadvantages of customised vs.
standardised longevity hedges
Disadvantages
Advantages
  • Cheaper than customised hedge
  • Lower set up and operational costs
  • More liquid, can be more easily unwound
  • Shorter maturity (generally) so counterparty
    credit risk is limited
  • Not a perfectly exact hedge
  • Population basis risk
  • Roll risk at maturity

Standardised Hedge
  • Exact hedge, no residual basis risk
  • Set-and-forget hedge, requires minimal monitoring
  • More expensive than standardised hedge
  • Higher set up and operational costs
  • Administration, documentation, monitoring, data
    provision
  • Poor liquidity, more difficult to unwind
  • Longer maturity leading to larger counterparty
    credit exposure
  • Less attractive to investors

I S S U E S   I N   H E D G I N G 
 L O N G E V I T Y   R I S K
Customised Hedge
Standardised hedge has advantages of simplicity,
liquidity and cost
11
14
Hedge effectiveness is an important concept in
evaluating potential hedges but is poorly
understood
  • A hedge can be less than 100 effective and still
    add value
  • The reinsurance paradigm for risk transfer means
    that this is not widely acknowledged. Insurance
    risk transfer is generally 100 effective
  • Longevity exposure is economically significant
  • Most hedges of financial risk are not 100
    effective
  • Few stakeholders in the longevity space
    understand hedge effectiveness
  • Hedge effectiveness is about risk reduction
  • Quantifying how a hedge reduces potential for
    monetary loss

I S S U E S   I N   H E D G I N G 
 L O N G E V I T Y   R I S K
12
15
Hedge effectiveness primer
  • Hedge effectiveness depends on objectives
  • Time horizon
  • Performance metric
  • Designated risk being hedged
  • Principles
  • Isolate the risk being hedged by removing impact
    of other risks
  • Define risk evaluation methodology carefully
    metric, data used
  • Relationship between hedge effectiveness and
    correlation can be counterintuitive
  • E.g. appropriate correlation measurement normal
    distribution
  • 80 correlation gt 40 risk reduction
  • 90 correlation gt 56 risk reduction
  • But a low year-on-year correlation can still lead
    to high hedge effectiveness if correlation is
    measured appropriately

Risk(ExposureHedge)
Risk Reduction 1-
Risk(Exposure)
Risk (mm)
Risk reduction ()
I S S U E S   I N   H E D G I N G 
 L O N G E V I T Y   R I S K
Source HEAT, Coughlan, Kolb and Emery 2003
13
16
The population basis risk associated with
standardised hedges can be managed
Correlations in mortality improvementsShort-term
correlations EW males aged 65
  • Basis risk by age can be managed
  • Since mortality improvements are highly
    correlated across age
  • Basis risk by socio-economic group can be managed
  • Short term correlations in mortality improvements
    have a low correlations
  • But mortality movements are correlated over the
    long term

Pension value EW males aged 65 CMI population vs
LifeMetrics hedge
I S S U E S   I N   H E D G I N G 
 L O N G E V I T Y   R I S K
14
17
Longevity risk transfer products in the capital
markets
A new market is emerging
1
1
Issues in hedging longevity risk
2
9
3
15
L O N G E V I T Y   R I S K   T R A N S F E R  
 C A P I T A L   M A R K E T   S O L U T I O N S 
15
18
Longevity risk transfer products could be based
on survivorship, life expectancy and/or mortality
rates
  • Successful products will best meet needs of all
    economic agents
  • Mortality rates are most likely to form the basis
    of liquid products
  • Simple building bocks
  • Allows creation of smallest number of instruments
  • Can be combined in a portfolio to replicate
    survivorship and life expectancy
  • Can be used by all hedgers pensions, annuity
    provides, life insurers, etc.

L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
16
19
Survivorship and life expectancy are not likely
to form the basis of a liquid market
  • Survivorship has the advantage that it directly
    reflects pension/annuity exposures
  • A function of mortality rates at different times
    and ages
  • Path dependency
  • Depends on starting year There as a many
    survival rates for 65 year olds as there are
    starting years (i.e. 65)
  • Inhibits fungibility of different contracts
    relating to same cohort
  • Difficult to hedge complex non-annuity exposures
  • Period life expectancy has the advantage of being
    more intuitive
  • A function of mortality rates for different ages
    at one time
  • Requires mortality rates for all ages above the
    age in question
  • Difficult to effectively hedge non-annuity
    exposures

L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
Mortality rates are likely to be a better basis
for a liquid market
17
20
q-Forwards are standardised derivatives for
transferring longevity and mortality risk
  • q-Forwards (mortality forwards)
  • Simple capital market instruments
  • Effectively a zero-coupon mortality swap
  • Exchange realised mortality rate in a future
    period for a pre-agreed fixed mortality rate

Term sheet for a single q-forward
Forward rate
L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
Net settlement at maturity for fixed rate receiver
1.2000
Realised mortality
18
21
q-Forwards can hedge pension/annuity and life
insurance liabilities
  • q-Forwards are building blocks
  • They can be combined into a portfolio to hedge
  • Pension liabilities
  • Annuity liabilities
  • Life insurance liabilities
  • A small set of standardised contracts can provide
    effective hedges
  • A specific maturity (e.g. 10 years)
  • Split by gender (males females)
  • Age groups (40-49, 50-59, 60-69, 70-79, 80-89)

Notional x 100x fixed mortality rate
Life Insurer
Hedge provider
Notional x 100 x realised mortality rate
Notional x 100x realised mortality rate
L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
Pension Plan/ Annuity book
Hedge provider
Notional x 100 x fixed mortality rate
19
22
Case study Application to hedging a DB pension
plan over a 10 year horizon
Cash flow profile Total (GBP mm)
  • Mature plan, fixed benefits
  • Impact of unexpected mortality improvements by 2
    per year compounded
  • Cash flow impact over horizon
  • Larger pension cash flows in years 1-10
  • Impact on liability value 0.76
  • Value impact in year 10
  • Large change in liability value
  • 13.2 of 2017 value
  • 9.6 due to higher survivorship
  • 3.6 due to mortality improvements beyond 10
    years

Increase in cash flow (GBP mm)
L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
Increase in liability value in 2017 ()
Improvements beyond 2017
Higher survivorship in 2017
20
23
Portfolio of q-Forwards can provide an effective
value and cash flow hedge
Hedge
Impact of Increase in trend of mortality
improvements
13.2
13.2
Pension liability (GBP mm)
L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
q-Forwards can hedge value and cash flow risk
21
24
How much does it cost?
Mortality rates of 65 year old EW males
(illustrative only)
  • Market is net short longevity
  • There are more economic agents with short
    longevity positions (pension plans, annuity
    providers, life settlements investors) than with
    a long position ( life insurers)
  • So to transfer longevity risk investors will
    require compensation
  • Mortality forward rate should be settled below
    the expected mortality rate

Best Estimate or Expected Mortality Curve
Forward Mortality Curve
Risk Premium
L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
  • In the early stages of the market, there will be
    no clear consensus of how to arrive at an agreed
    objective expectation of future mortality rates
  • Lee-Carter model? - (relatively) simple and
    transparent
  • Official forecasts? - Government, society of
    actuaries

22
25
Conclusions
  • Longevity is emerging as a good candidate to
    become a new market
  • The development of liquidity requires
  • Standardisation
  • Education
  • Hedgers (pension plans annuity providers) need
    to better understand
  • Concepts of hedge effectiveness
  • You dont have to transfer 100 of the risk to
    add value
  • Basis risk can be managed
  • A liquid market requires standardised instruments
  • Concentrate liquidity in a small number of
    contracts initially
  • q-Forwards are a good candidate for developing a
    liquid market

L O N G E V I T Y   R I S K   T R A N S F E R 
 P R O D U C T S   I N   T H E   C A P I T A L 
 M A R K E T S
23
Write a Comment
User Comments (0)
About PowerShow.com